← Back to Search

GLP-1 RA group for Chronic Kidney Disease

N/A
Waitlist Available
Led By Alexander Abitbol, MD
Research Sponsored by LMC Diabetes & Endocrinology Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 26-to-52 weeks follow-up
Awards & highlights

Study Summary

The overall objective of this study is to compare the effectiveness of adding a glucagon-like peptide-1 receptor agonist compared with adding basal insulin for patients with type 2 diabetes and chronic kidney disease, already treated with an sodium-glucose cotransporter-2 inhibitor and not currently reaching target glycemic control. All sociodemographic information and clinical variables will be retrieved from the LMC Diabetes Registry.

Eligible Conditions
  • Chronic Kidney Disease
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 26-to-52 weeks follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 26-to-52 weeks follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
change in HbA1c (%)

Trial Design

2Treatment groups
Experimental Treatment
Group I: basal insulin groupExperimental Treatment1 Intervention
adult patients with T2D and CKD who initiated basal insulin therapy
Group II: GLP-1 RA groupExperimental Treatment1 Intervention
adult patients with T2D and CKD who initiated GLP-1 RA therapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GLP-1 receptor agonist
2020
Completed Phase 3
~11540
basal insulin
2016
Completed Phase 4
~32790

Find a Location

Who is running the clinical trial?

LMC Diabetes & Endocrinology Ltd.Lead Sponsor
16 Previous Clinical Trials
22,535 Total Patients Enrolled
Novo Nordisk Canada Inc.UNKNOWN
Alexander Abitbol, MDPrincipal InvestigatorLMC Diabetes & Endocrinology Ltd.
1 Previous Clinical Trials
240 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease
2023. "Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06236672.
~161 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top